Navigation Links
Acuity One-Year Findings Meet All Primary Endpoints in Favor of,Angiomax (Bivalirudin) Alone Treatment Group

Major Bleeding in Patients Treated for Acute Coronary Syndromes (ACS) Nearly Triples the Risk of Death at One Year

NEW ORLEANS, March 26, 2007 /PRNewswire/ -- One-year findings from the landmark ACUITY trial show that acute coronary syndrome (ACS) patients in the "Angiomax(R) (bivalirudin) alone" treatment group had similar rates of ischemic clinical outcomes compared with more complicated standard therapy, confirming previous findings, which showed similar ischemia at 30 days, and nearly 50% fewer episodes of major bleeding. At one year, the mortality rate of patients treated in the Angiomax alone treatment group was 3.8%, compared to 4.4% in the control treatment group. A separate analysis found that, in patients with ACS, having a major bleeding episode within 30 days following treatment nearly triples the risk of death up to one year later, making major bleeding a more powerful predictor of mortality than even a heart attack.

The ACUITY one-year results were presented as late-breaking findings by investigators for the first time here at the i2 Summit at the 56th Annual Scientific Session of the of Cardiology. Collectively, the data showed that ACUITY met all primary one-year endpoints and confirmed previously published 30-day findings. The Medicines Company markets Angiomax, an anti-clotting agent, in the United States.

"Our findings are important because they demonstrate that in high risk patients with ACS, Angiomax, the simplest and least expensive regimen, results in the overall best clinical outcomes," said ACUITY's principal investigator, Gregg W. Stone, MD, professor of medicine and director of cardiovascular research and education at Medical Center's Center for Interventional Vascular Therapy, and chairman of the Cardiovascular Research Foundation.

Study Findings

The one-year ACUITY analysis showed that treatment in the Angiomax(R)(bivalirudin) alone group resulted in comp
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. New One-Year Pharmacoeconomic Study Shows Avonex is Cost-Effective Relative to Other Interferon Therapies for Multiple Sclerosis
2. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Molecular Target of Bradmers Neuradiab Further Validated by Independent Findings
5. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
6. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
7. Haemacure Announces Preliminary Findings of its Plasma Discard Analysis
8. EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3 Clinical Trial at 47th Annual NCDEU Meeting
9. Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune Deficiency
10. Prana Biotechnology Presents New Key Findings on PBT2
11. Investigation Findings, Corroborated by Empirical Evidence of the Schisandra Berry as Cardio-Tonic in Traditional Chinese Medicine for Hundreds of Years, Support the Use of Schisandrin B in the Prevention and Treatment of IHD
Post Your Comments:
(Date:5/27/2015)... -- The prevalence of cardiovascular disease in ... and changes in consumption concept, dietary habit, way of ... year, thereby promoting the development of domestic percutaneous coronary ... totaled 454,505 in 2013, up 16.9% from ... there was worth RMB20.12 billion. At present, half ...
(Date:5/27/2015)... 2015 Research and Markets ( ... "North America Portable X Ray Devices Market - ... to their offering.       (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... market for Portable X-Ray Devices is expected ... to 2020 X-Ray is a form ...
(Date:5/27/2015)... WORTH, Texas , May 27, 2015 ... defines and segments the concerned market with analysis and ... $1,017.8 million by 2019 and is estimated to grow ... 2019. Browse through the TOC of the ... idea of the in-depth analysis provided. This report also ...
Breaking Medicine Technology:China Interventional Cardiovascular Device Industry Report, 2014-2017 2China Interventional Cardiovascular Device Industry Report, 2014-2017 3North America Portable X Ray Devices Market Report 2015 - Growth, Trends And Forecasts 2014-2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 2Vitreoretinal Surgery Devices Market is Expected to Reach $1,017.8 Million by 2019, at a CAGR of 8.9 % From 2014 to 2019 3
... Corporation (Nasdaq: DNDN ) announced today that ... remainder of its New Jersey manufacturing facility, allowing the ... to help meet the needs of patients with asymptomatic ... cancer.   Last April, upon receiving FDA ...
... Hospital and SynCardia Systems, Inc. announced today that Texas ... complete the first phase of certification to implant the ... use the Total Artificial Heart as a bridge to ... as children and now require mechanical support as a ...
Cached Medicine Technology:Dendreon Expands Launch of PROVENGE 2Dendreon Expands Launch of PROVENGE 3Dendreon Expands Launch of PROVENGE 4Dendreon Expands Launch of PROVENGE 5Texas Children's Is First Pediatric Hospital To Begin Certification Process for SynCardia's Total Artificial Heart 2Texas Children's Is First Pediatric Hospital To Begin Certification Process for SynCardia's Total Artificial Heart 3
(Date:5/27/2015)... 2015 Dr. Omar Ibrahimi, Dermatologist and ... CT has been selected as part of a controlled ... (and the only physician in Connecticut) to offer the ... the removal of submental fat (double chin). The procedure ... no surgery and minimal risks. Dr. Ibrahimi is an ...
(Date:5/27/2015)... Clearwater, Florida (PRWEB) May 27, 2015 ... accurate, impartial customer satisfaction surveys in the multiple ... user poll to determine the highest ranked Electronic ... As part of a special research focus on ... and announced those software vendors with the highest ...
(Date:5/27/2015)... Rock, AR (PRWEB) May 27, 2015 ... Medix today announce a partnership to provide CMSA's ... Medix community. This collaboration seeks to strengthen the ... measurement through CMSA’s CKP program. The mutually beneficial ... on identifying individual skills of talent in the ...
(Date:5/27/2015)... 27, 2015 Difass USA, a modern ... U.S. with its first three flagship products, Dormiva™, Relaxiva™ ... nationwide through http://www.difassusa.com . , A restful ... productivity, but some people struggle with getting the full ... a sleep aid designed to help you fall asleep ...
(Date:5/27/2015)... On June 5, Plan B [the ... with LifeSource to host Donate Your Break, a public ... a LifeSource donor coach outside of 116 W. Illinois ... Demand for whole blood units is highest for LifeSource, ... months. LifeSource requires approximately 1,000 donations per day to ...
Breaking Medicine News(10 mins):Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 2Health News:Connecticut Skin Institute First in Connecticut to Offer New Surgery-Free “Double Chin” Fat Reduction Treatment 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 2Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 3Health News:Cloud-Based Electronic Health Record firms sweep top physician satisfaction rankings for Small and Solo Practices, reveals 2015 Black Book survey 4Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 2Health News:Case Management Society of America Partners with Medix to Offer Career and Knowledge Pathways 3Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2Health News:Donate Your Break and Save Lives at the River North Blood Drive 2
... the University of Minnesota have found that cerebral malaria is related ... research is published in the current issue of the journal ... Malaria is a leading cause of death ... than 750,000 children a year, is one of the deadliest forms ...
... Mich., July 29 Stryker Corporation,(NYSE: SYK ) ... conference:, August 6, 2008 - 11:15 a.m. ... Conference New York, New York, A simultaneous ... website at http://www.stryker.com via the For Investors ...
... show that regular,monitoring of medications by physicians is ... health. Thanks to recent advances in the SMART,Registry, ... about their,patients that they never received before., ... how regularly,their chronically ill patients fill their prescriptions., ...
... developed a novel approach to treating advanced prostate cancer ... , Professor Wayne Tilley and Dr Lisa Butler of ... discovered that by using existing prostate cancer drugs in ... expect to generate better results for patients than current ...
... up in motor neurons , , TUESDAY, July 29 (HealthDay ... amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig,s ... University and Harvard Medical School. , ALS is a ... neurons in the brain and spinal cord that control ...
... the Clinical Gold Standard Drug Through 2016, According ... to a New Report from Decision Resources, ... the,world,s leading research and advisory firms focusing on pharmaceutical and,healthcare ... has a lower discontinuation rate than that of Abbott,s,Niaspan ER ...
Cached Medicine News:Health News:U of M researchers find cerebral malaria may be a major cause of brain injury in African children 2Health News:Stryker To Present at Investor Conference 2Health News:Highmark's SMART(TM) Registry Reports Aid the Chronically Ill 2Health News:Highmark's SMART(TM) Registry Reports Aid the Chronically Ill 3Health News:New treatment for advanced prostate cancer 2Health News:Scientists ID 'Jekyll-Hyde' Protein in Lou Gehrig's Disease 2Health News:A High-Density Lipoprotein Raising Drug That Has a Lower Discontinuation Rate Than That of Extended Release Niaspan Would Earn a 20 Percent Patient Share in the Dyslipidemia Drug Market 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: